Stereotactic Body Radiotherapy for Patients with Lung Oligometastatic Disease: A Five-Year Systematic Review.
Guillaume VirbelClara Le FèvreGeorges NoëlDelphine AntoniPublished in: Cancers (2021)
For several years, oligometastatic disease has represented an intermediate state between localized disease accessible to local treatment and multimetastatic disease requiring systemic therapy. The lung represents one of the most common metastatic locations. Stereotactic body radiation therapy (SBRT) appears to be the treatment of choice for these patients. There are few data defining the place of radiotherapy and reporting outcome after SBRT in lung metastases. This 5-year review aimed to determine areas of SBRT usefulness and methods for the management of pulmonary metastasis in oligometastatic patients. A search for articles on PubMed allowed selection of the most relevant studies. Eighteen articles were selected according to pre-established criteria for this purpose. The analysis concludes that SBRT is an effective and safe treatment in selected patients when the disease remains localized from one to three organs.
Keyphrases
- radiation therapy
- systematic review
- end stage renal disease
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- early stage
- small cell lung cancer
- peritoneal dialysis
- emergency department
- randomized controlled trial
- locally advanced
- radiation induced
- patient reported outcomes
- electronic health record
- mesenchymal stem cells
- smoking cessation
- deep learning
- big data
- replacement therapy